Interview Questions for Asthma Diagnosis and Treatment

Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways. Imagine your airways as flexible tubes; in asthma, these tubes become inflamed and constricted, making it difficult to breathe. This pathophysiology involves several key players:

• Airway Inflammation: The airways become inflamed due to an immune response triggered by allergens (like pollen or dust mites), irritants (like smoke or cold air), or even exercise. This inflammation leads to swelling and mucus production.
• Airway Hyperresponsiveness: The airways become excessively sensitive and react strongly to even minor triggers, causing further constriction.
• Airway Remodeling: Over time, chronic inflammation can lead to structural changes in the airways, thickening the walls and further reducing airflow. This is a progressive process and contributes to the worsening of asthma over time.
• Bronchoconstriction: The muscles surrounding the airways tighten, further narrowing the passageways and restricting airflow. This is a major contributor to the wheezing and shortness of breath experienced during an asthma attack.

In essence, the interplay of inflammation, hyperresponsiveness, remodeling, and bronchoconstriction creates the characteristic symptoms of asthma.

Asthma isn’t a one-size-fits-all condition. Several subtypes are recognized, primarily based on triggers and severity:

• Allergic Asthma: Triggered by specific allergens like pollen, dust mites, pet dander, or cockroaches. This is the most common type.
• Non-allergic Asthma: Triggered by factors other than allergens, such as viral infections, exercise, cold air, or irritants like smoke.
• Exercise-Induced Asthma (EIA): Asthma symptoms triggered specifically by physical activity. This is often caused by dehydration and/or airway cooling.
• Occupational Asthma: Asthma caused by exposure to specific substances in the workplace, such as chemicals, dust, or animal proteins.
• Late-Onset Asthma: Asthma developing in adulthood.

It’s crucial to identify the specific subtype of asthma to tailor treatment effectively. For example, someone with allergic asthma will benefit from allergen avoidance and immunotherapy, while someone with exercise-induced asthma might require preventative medication before physical activity.

An asthma attack is a significant worsening of asthma symptoms, which can be life-threatening if not treated promptly. Key symptoms include:

• Wheezing: A whistling sound during breathing, caused by narrowed airways.
• Shortness of Breath: Difficulty breathing, often feeling like you can’t get enough air.
• Coughing: A persistent cough, often worse at night.
• Chest Tightness: A feeling of pressure or tightness in the chest.
• Increased sputum production: Production of thick mucus.

The severity of these symptoms can range from mild discomfort to a severe, life-threatening emergency requiring immediate medical attention. A hallmark of asthma attacks is the variability of symptoms, meaning they can improve and worsen over time.

Diagnosing asthma involves a combination of assessing symptoms, conducting physical examinations, and performing diagnostic tests. The process is iterative and may involve multiple visits.

1. Detailed Medical History: Thorough questioning about the patient’s symptoms, frequency, duration, triggers, family history of asthma, and response to previous treatments.
2. Physical Examination: Listening to the patient’s lungs for wheezing and assessing their overall respiratory status.
3. Spirometry and Peak Expiratory Flow Rate (PEFR): Objective tests to measure lung function (discussed in more detail in the next question).
4. Allergy Testing (if indicated): Skin prick tests or blood tests to identify specific allergens that may be contributing to asthma.
5. Imaging Studies (occasionally): Chest X-rays or CT scans may be used to rule out other respiratory conditions or to assess the severity of the inflammation.

The diagnosis is based on a pattern of symptoms, evidence of airway obstruction on spirometry, and response to bronchodilator therapy. The severity of asthma is classified based on symptoms, lung function tests, and the need for medication.

Two key diagnostic tests for asthma are spirometry and peak flow meter.

• Spirometry: This is the gold standard test for assessing lung function. It measures how much air a person can inhale and exhale and how quickly they can exhale. A spirometer measures several parameters, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). A significant reduction in FEV1 and an improvement after bronchodilator administration (like albuterol) is highly suggestive of asthma. Imagine blowing into a tube connected to a machine that measures airflow. The results provide objective data on airway obstruction.
• Peak Flow Meter: A handheld device that measures the patient’s peak expiratory flow rate (PEFR). This is the maximum speed at which a person can exhale. PEFR monitoring can help track asthma control over time and identify potential exacerbations. It’s less precise than spirometry but is useful for self-monitoring at home.

Both tests provide valuable insights into the severity of airflow limitation and the responsiveness of the airways to treatment. They are essential components in the diagnosis and management of asthma.

Interpreting a spirometry report indicating asthma involves looking for specific patterns. A patient with asthma will typically demonstrate:

• Reduced FEV1/FVC ratio: This is the most important indicator. The ratio will be lower than the predicted value for the patient’s age, height, and sex. This signifies airway obstruction.
• Low FEV1: This indicates that the patient is not able to exhale as much air in one second as expected.
• Significant improvement in FEV1 after bronchodilator administration: A notable increase in FEV1 (typically greater than 12%) after inhaling a bronchodilator such as albuterol strongly supports the diagnosis of asthma.

Example: A patient’s spirometry shows an FEV1/FVC ratio of 65% (below the predicted 80%), a low FEV1, and a 15% increase in FEV1 after albuterol. This pattern is highly suggestive of asthma.

It’s essential to consider the patient’s clinical history and other findings to make a definitive diagnosis. Spirometry results alone are not sufficient for a diagnosis, but they provide crucial objective data.

Asthma medications are broadly classified into two categories: relievers and controllers.

• Relievers (Bronchodilators): These medications provide quick relief from asthma symptoms. They work by relaxing the muscles around the airways, widening them and improving airflow. The most common relievers are:
• Short-acting β2-agonists (SABAs): Such as albuterol (Ventolin), provide rapid relief of symptoms. These medications are for immediate symptom relief and should not be used for long-term control.
• Short-acting anticholinergics: Like ipratropium, can be used in combination with SABAs for quicker symptom relief.
• Controllers (Preventative Medications): These medications are taken regularly to prevent asthma symptoms and reduce the frequency and severity of exacerbations. They work by reducing airway inflammation. The main classes of controllers include:
• Inhaled corticosteroids (ICS): Such as fluticasone (Flovent), are the cornerstone of asthma control. They decrease inflammation in the airways.
• Long-acting β2-agonists (LABAs): Such as salmeterol (Serevent), are used in combination with ICS to provide long-term bronchodilation. They should never be used alone.
• Leukotriene modifiers: Such as montelukast (Singulair), block the action of leukotrienes, inflammatory chemicals involved in asthma.
• Biologic therapies: These are newer targeted therapies for severe asthma, specifically targeting key inflammatory pathways (e.g., omalizumab, dupilumab).

The choice of medication and dosage depends on the severity of the asthma, the patient’s response to treatment, and the presence of comorbid conditions. A comprehensive treatment plan involves regular monitoring of lung function and adjusting medication as needed.

Asthma management centers around preventing symptoms, minimizing exacerbations, and maintaining normal lung function. It’s a personalized approach, tailored to the individual’s needs and severity of their condition. The core principles involve:

• Identifying and controlling triggers: This is paramount. Triggers vary widely, from allergens like pollen and pet dander to irritants such as smoke and air pollution. Identifying and avoiding these is crucial.
• Regular medication use: This includes both controller medications (daily medications to prevent symptoms) and reliever medications (used for quick relief during an attack).
• Monitoring lung function: Regular monitoring, often using a peak flow meter, helps assess asthma control and identify early warning signs of worsening symptoms.
• Patient education and self-management: Empowering patients to understand their condition and actively participate in their treatment is vital. This includes knowing when and how to use their inhalers, recognizing warning signs, and developing an action plan.
• Regular follow-up with healthcare providers: Consistent monitoring and adjustments to treatment plans based on patient response are essential.

Think of it like managing a chronic condition like diabetes – consistent effort is key to maintaining good health and preventing serious complications.

The stepwise approach to asthma management is a structured way to tailor treatment to the individual’s needs. It begins with assessing the severity and progresses based on response to therapy. It typically involves these steps:

1. Step 1 (Mild Intermittent): This involves occasional symptoms and normal lung function between exacerbations. Treatment might involve a short-acting beta-agonist (SABA) like albuterol, used only as needed for symptom relief.
2. Step 2 (Mild Persistent): More frequent symptoms and some limitation of activity. Treatment typically adds a low-dose inhaled corticosteroid (ICS).
3. Step 3 (Moderate Persistent): Daily symptoms, more frequent exacerbations, and moderate limitation of activity. Treatment may involve increasing the ICS dose or adding a long-acting beta-agonist (LABA).
4. Step 4 (Severe Persistent): Frequent symptoms, significant limitation of activity, and frequent exacerbations. Treatment may involve high-dose ICS, LABA, and potentially other medications like leukotriene modifiers or oral corticosteroids.

The steps aren’t rigid; adjustments are made based on the patient’s response. If symptoms improve, the treatment might be stepped down. If symptoms worsen, the treatment is stepped up.

Managing an acute asthma exacerbation requires prompt and decisive action. The initial steps involve assessing the severity of the exacerbation, providing oxygen, and administering bronchodilators (usually a short-acting beta-agonist like albuterol via nebulizer or metered-dose inhaler with a spacer).

If there’s no significant improvement or the patient shows signs of severe respiratory distress, immediate medical intervention is critical. This may involve:

• Systemic corticosteroids: Oral or intravenous corticosteroids to reduce airway inflammation.
• High-flow oxygen therapy: To improve oxygen saturation.
• Nebulized bronchodilators: Continuous nebulization of bronchodilators may be necessary.
• Magnesium sulfate: In severe cases, this can provide additional bronchodilation.
• Intubation and mechanical ventilation: As a last resort, if the patient is not responding to other treatments and is in respiratory failure.

Monitoring vital signs (heart rate, respiratory rate, oxygen saturation) is crucial throughout the process. The patient’s response to treatment dictates further management.

Severe asthma requiring immediate intervention is characterized by:

• Inability to speak in sentences: This is a critical sign indicating severe airflow limitation.
• Silent chest: Absence of breath sounds indicating severe airway obstruction.
• Use of accessory muscles for breathing: The patient might be using neck and chest muscles to breathe, indicating respiratory distress.
• Paradoxical breathing: Abdominal breathing that’s out of sync with chest breathing.
• Decreased or absent wheezing: This can be paradoxical – it often indicates severe airway obstruction.
• Bradycardia or tachycardia: Abnormal heart rate.
• Cyanosis: Bluish discoloration of the lips and nail beds due to low blood oxygen levels.
• Altered mental status: Confusion, lethargy, or unresponsiveness.

These signs indicate a medical emergency and require immediate hospital admission for intensive respiratory support.

Poorly controlled asthma can lead to several serious complications, including:

• Frequent exacerbations: Leading to hospitalizations and reduced quality of life.
• Permanent lung damage: Chronic inflammation and airway remodeling can lead to irreversible decline in lung function.
• Respiratory failure: Severe airway obstruction can lead to inadequate gas exchange and life-threatening respiratory failure.
• Cardiovascular complications: Asthma is associated with an increased risk of heart problems, including heart attacks and strokes.
• Increased risk of infections: Compromised lung function can increase susceptibility to respiratory infections.
• Anxiety and depression: The constant worry and fear associated with asthma can negatively impact mental health.

These complications highlight the importance of proactive asthma management to prevent long-term health consequences.

Assessing asthma control involves a multifaceted approach that considers various aspects:

• Symptom assessment: Frequency and severity of symptoms like wheezing, cough, shortness of breath, and chest tightness.
• Peak flow monitoring: Regular peak flow measurements help track lung function and identify early warning signs of worsening asthma.
• Medication use: Frequency of reliever medication use is a key indicator of asthma control. Frequent use suggests poor control.
• Night-time awakenings: Frequent awakenings due to asthma symptoms are indicative of poor control.
• Activity limitations: Assessment of how asthma affects daily activities and exercise tolerance.
• Asthma Control Test (ACT): A validated questionnaire that assesses various aspects of asthma control and provides a numerical score.

A comprehensive assessment helps tailor the treatment plan to optimize control and minimize risks.

Patient education is the cornerstone of effective asthma management. It empowers individuals to actively participate in their care and make informed decisions.

• Understanding the disease: Explaining asthma’s pathophysiology, triggers, and symptoms helps patients understand their condition.
• Inhaler technique: Proper inhaler technique is vital for medication effectiveness. Demonstration and practice are essential.
• Action plan development: Creating a personalized action plan outlines steps to take based on symptom severity and peak flow readings.
• Trigger identification and avoidance: Helping patients identify their personal triggers and develop strategies to avoid or minimize exposure is key.
• Self-monitoring techniques: Teaching patients how to use peak flow meters and record their symptoms enables early detection of worsening asthma.
• Medication adherence: Emphasizing the importance of regular medication use, even when symptom-free, is crucial.
• Emergency preparedness: Educating patients on when to seek medical attention and what to expect during an exacerbation is vital.

Effective patient education leads to better disease control, fewer exacerbations, and improved quality of life.

Peak flow monitoring is crucial in asthma management because it allows us to objectively measure the airflow from the lungs. This helps assess the severity of asthma symptoms and track the effectiveness of treatment. Think of it as a vital sign specifically for your lungs.

A peak flow meter is a small, handheld device that measures the highest speed of air you can exhale in one forceful breath. By recording your peak flow daily, you can identify patterns and early warnings of worsening asthma. For example, if your peak flow consistently drops below your personal best (usually 80% or less), it’s a clear signal that your asthma is worsening and may require intervention, like adjusting medications or seeking medical attention.

Regular peak flow monitoring empowers patients to actively manage their asthma, preventing potentially serious exacerbations. It’s like having a personalized early warning system for your lungs.

Differentiating asthma from other respiratory conditions can be challenging, as many share similar symptoms like wheezing, coughing, and shortness of breath. A thorough history, physical examination, and specific tests are necessary.

• Chronic Obstructive Pulmonary Disease (COPD): Typically affects older smokers and is characterized by progressive airflow limitation, primarily from emphysema and chronic bronchitis. Unlike asthma, COPD typically doesn’t respond well to bronchodilators, and peak flow variability is often less pronounced.
• Bronchitis: This is usually an acute inflammation of the bronchial tubes, often caused by a viral infection. While symptoms can overlap with asthma, bronchitis is usually self-limiting and resolves within a few weeks.
• Pneumonia: An infection of the lungs that causes inflammation and fluid buildup. It often presents with fever, chills, and more significant respiratory distress than asthma.
• Gastroesophageal Reflux Disease (GERD): While not a respiratory condition, GERD can trigger or worsen asthma symptoms through acid reflux irritating the airways. Careful history taking about heartburn or acid reflux is vital.

Spirometry, a test that measures lung function, is a critical tool. Asthma typically shows reversible airway obstruction after using a bronchodilator, while COPD shows a less reversible or irreversible airflow limitation. Other tests, such as allergy testing or imaging, might be needed to confirm the diagnosis.

Asthma exacerbations are triggered by a variety of factors, which are often unique to each individual. Common triggers include:

• Allergens: Dust mites, pollen, pet dander, mold spores. These are common culprits and often identified through allergy testing.
• Irritants: Smoke (cigarette, wood, etc.), air pollution, strong odors (perfumes, cleaning products).
• Infections: Viral respiratory infections (colds, flu) are frequently linked to asthma exacerbations.
• Exercise: While exercise is beneficial overall, vigorous physical activity can trigger asthma in susceptible individuals.
• Weather changes: Cold air, particularly dry cold air, can trigger bronchoconstriction.
• Stress and emotions: Psychological stress can exacerbate asthma symptoms.
• Medications: Some medications, such as NSAIDs (non-steroidal anti-inflammatory drugs), can trigger asthma in some patients.

Understanding these triggers is key to individualized asthma management.

Counseling patients on avoiding asthma triggers is a crucial part of asthma management. This is a collaborative process, focusing on patient education and empowerment.

• Allergen control: This involves strategies like regular cleaning, use of dust mite-proof covers, avoiding exposure to pets, and appropriate ventilation to reduce mold.
• Irritant avoidance: This includes avoiding smoke, air pollution (by checking air quality reports), and strong odors. Wearing masks in polluted environments can be helpful.
• Infection prevention: Practicing good hygiene, getting flu shots, and managing other health issues that might increase susceptibility to infections.
• Exercise management: Warming up before exercise and using a preventative inhaler before physical activity.
• Stress management techniques: Yoga, meditation, deep breathing exercises, and stress reduction techniques.

Patient education materials and personalized action plans significantly improve adherence to trigger avoidance strategies.

Allergy testing plays a vital role in asthma management, especially in identifying specific allergens that trigger exacerbations. Common tests include skin prick tests and blood tests (e.g., IgE antibody tests). Knowing the specific allergens that trigger a patient’s asthma enables targeted avoidance strategies and, in some cases, allergen-specific immunotherapy (allergy shots).

For example, if a patient’s allergy testing reveals a strong sensitivity to cat dander, we can counsel them on reducing exposure to cats or, if necessary, consider allergen immunotherapy. This personalized approach is far more effective than generic advice.

Managing asthma during pregnancy requires careful consideration as both maternal and fetal well-being are paramount. The goal is to maintain good asthma control throughout pregnancy while minimizing the risk of adverse effects from medications.

Inhaled corticosteroids are generally considered safe and effective during pregnancy and are usually the first-line treatment. However, certain medications, like leukotriene modifiers or long-acting beta-agonists, might need to be adjusted based on individual patient needs and response. Regular monitoring of both maternal asthma symptoms and fetal development is vital. Close collaboration between the obstetrician and pulmonologist ensures optimal management.

It’s important to note that uncontrolled asthma poses a greater risk to both mother and baby than appropriately managed asthma with medication. Therefore, prioritizing good asthma control is crucial.

Managing asthma in children differs from adults in several aspects:

• Diagnosis: Diagnosing asthma in children can be more challenging due to their variable symptoms and less reliable spirometry results. History, physical exam, and response to bronchodilators play a more significant role.
• Medication: Dosage and types of medications are adjusted based on age and weight. Spacer devices are frequently used with inhalers in children to improve drug delivery.
• Triggers: Triggers can vary, with infections playing a more significant role in younger children.
• Education: Patient and family education are crucial in managing childhood asthma, emphasizing the importance of adherence to treatment and identification of potential triggers.

In adults, we focus on more sophisticated assessment of lung function, potentially including advanced testing like bronchial provocation tests. Adult patients have more experience managing their condition and may have greater responsibility in self-management.

Ethical considerations in asthma management are multifaceted and center around patient autonomy, beneficence, and justice. It’s crucial to ensure patients understand their diagnosis, treatment options, and potential risks and benefits, allowing them to make informed decisions. This involves clear communication, tailored to the patient’s health literacy. Beneficence requires us to act in the patient’s best interest, balancing the potential benefits of treatment against potential side effects. Justice mandates equitable access to quality asthma care, regardless of socioeconomic status, race, or geographic location. This includes addressing disparities in healthcare access and ensuring affordable medications.

For example, a patient might be hesitant to use inhaled corticosteroids due to concerns about side effects. Ethically, we must address these concerns through open dialogue, providing evidence-based information to help them weigh the benefits (reduced exacerbations, improved lung function) against the risks (e.g., thrush, voice changes). We must also explore alternative management strategies when possible and ensure the patient feels heard and respected throughout the process. Similarly, we must advocate for policies that improve access to care and affordable medications for all patients, regardless of their background.

Inhaled corticosteroids (ICS) are cornerstone medications in asthma management. They are potent anti-inflammatory agents that reduce airway inflammation, a key driver of asthma symptoms. ICS work by suppressing the activity of inflammatory cells, such as eosinophils and mast cells, thus reducing airway hyperresponsiveness, mucus production, and bronchoconstriction. They are particularly effective in preventing asthma exacerbations and improving lung function in patients with persistent asthma.

ICS are typically used as a preventative treatment, rather than a quick-relief medication. They are often administered daily, even when symptoms are well controlled. This helps to maintain a low level of inflammation, preventing future attacks. Different ICS formulations, such as inhalers or nebulizers, provide flexibility in delivery methods based on individual patient needs and preferences. Examples include fluticasone, budesonide, and beclomethasone.

Think of ICS as a preventative measure similar to taking a daily aspirin to prevent heart attacks. While you may not feel the immediate benefit, it significantly reduces the risk of future serious events.

Long-term use of asthma medications, particularly inhaled corticosteroids, can lead to some potential side effects. The severity and frequency of these side effects vary greatly depending on the medication, dosage, and individual patient factors. Common side effects of ICS include oral thrush (candidiasis), hoarseness, and throat irritation. These are often easily manageable with proper mouth rinsing after inhaler use or by switching to a different ICS formulation.

Less common but more serious side effects, particularly with high doses or long-term use, include bone loss (osteoporosis), cataracts, and glaucoma. Regular monitoring of bone density, eye examinations, and careful consideration of the dose are crucial to minimize these risks. Other potential side effects can include bruising and increased risk of infections. It is critical to weigh the benefits of reducing asthma exacerbations against the risks of potential side effects when prescribing long-term medications. Open communication with the patient regarding potential side effects and strategies for managing them is essential for ensuring adherence to the treatment plan.

Bronchodilators are medications that relax the muscles around the airways, widening them and making it easier to breathe. They provide quick relief from asthma symptoms such as wheezing, shortness of breath, and chest tightness. They are used as rescue medications during an asthma exacerbation or as a preventative medication in certain cases.

There are two main types of bronchodilators: short-acting beta2-agonists (SABAs) and long-acting beta2-agonists (LABAs). SABAs, such as albuterol (salbutamol), provide rapid relief for acute symptoms and are typically used as needed. LABAs, such as salmeterol and formoterol, provide longer-lasting relief and are often used in combination with ICS in patients with persistent asthma. However, LABAs should not be used alone and are always prescribed in conjunction with an ICS for long-term control of asthma.

Think of SABAs as firefighters – they quickly put out the immediate fire (asthma symptoms). LABAs are more like preventative measures – they help reduce the likelihood of future fires (exacerbations). Using them together ensures both immediate relief and long-term protection.

Monitoring the effectiveness of asthma treatment involves a multi-pronged approach, focusing on both objective and subjective measures. Objective measures include regular assessment of lung function using spirometry (measuring forced expiratory volume in one second, FEV1) and peak expiratory flow (PEF) monitoring. These tests provide quantifiable data on the patient’s lung capacity and airway responsiveness.

Subjective measures include assessing the patient’s symptoms, frequency of exacerbations, and quality of life. This involves regular discussions with the patient about their symptoms, nighttime awakenings, activity limitations, and overall well-being. We use standardized questionnaires to quantify symptom severity and impact on daily life. Consistent monitoring allows for timely adjustments to the treatment plan to optimize asthma control and minimize exacerbations. For example, if spirometry shows a decline in FEV1, or the patient reports increased symptoms, we may adjust medication doses or consider adding additional therapies.

Managing severe refractory asthma, defined as asthma poorly controlled despite high-dose ICS and LABA therapy, is a significant clinical challenge. My approach involves a thorough assessment of the patient’s history, including triggers, exacerbations, and medication adherence. We conduct detailed investigations such as allergy testing, blood tests to assess eosinophilic inflammation, and sometimes imaging studies to rule out other conditions.

Treatment strategies for severe asthma often involve increasing ICS doses to the maximum tolerated level, adding other controllers like omalizumab (anti-IgE antibody) or mepolizumab (anti-IL-5 antibody) which target specific inflammatory pathways, and potentially using long-acting muscarinic antagonists (LAMAs) in addition to ICS/LABA. In some cases, referral to a pulmonologist specializing in severe asthma may be necessary to consider more complex therapies, such as biologics or even referral to an allergist for immunotherapy. Close monitoring, including regular spirometry, blood tests and symptom assessments are crucial to ensure treatment efficacy and adjust the management plan as needed. Open communication and collaboration with the patient and their family is essential throughout this process.

A memorable case involved a young woman with severe eosinophilic asthma unresponsive to conventional therapy. After extensive testing and discussions, we added a targeted biologic therapy, leading to a significant improvement in her lung function and quality of life. This highlights the importance of a personalized approach to managing severe refractory asthma.

Environmental factors play a significant role in asthma prevalence and severity. Exposure to indoor and outdoor allergens, such as dust mites, pet dander, pollen, and mold, can trigger inflammatory responses in the airways, exacerbating asthma symptoms. Air pollution, including particulate matter and ozone, is also strongly linked to increased asthma prevalence and exacerbations. Studies have shown a correlation between higher levels of air pollution and increased hospital admissions for asthma.

Other environmental factors include exposure to tobacco smoke (both active and passive smoking), occupational exposures to certain chemicals or irritants, and even climate change, which can influence allergen seasons and increase the overall burden of respiratory illnesses. Reducing exposure to these triggers is a crucial component of asthma management. This includes strategies such as allergen avoidance (e.g., using dust mite covers, avoiding smoking), improving indoor air quality (e.g., using air purifiers, reducing humidity), and advocating for stricter air pollution control measures. Understanding and managing these environmental factors significantly impact the prevention and control of asthma.